Eli Lilly's nationwide insulin pricing settlement called off

A settlement between Eli Lilly (LLY.N) and purchasers of its insulin drugs that would have capped prices and provided $13.5 million to resolve claims that the company inflated the drugs' cost has fallen apart, after an unfavorable ruling from the judge overseeing the case.